Temozolomide

$ 1.00 /1KG

Min. Order1G
Purity98%
Cas No85622-93-1
Supply Ability100KG
Update time2019-07-06

career henan chemical co

VIP8Y

China

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	Temozolomide
CAS No	85622-93-1
EC-No
Min. Order	1G
Purity	98%
Supply Ability	100KG
Release date	2019/07/06

AD68

Product Name:	Temozolomide
Synonyms:	4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide;TEMOZOLOMIDE;1-d)(1,2,3,5)tetrazine-8-carboxamide,3,4-dihydro-3-methyl-4-oxo-imidazo(;3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide;3-methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide;8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3h)-one;ccrg81045;m&b39831
CAS:	85622-93-1
MF:	C6H6N6O2
MW:	194.15084
EINECS:	1308068-626-2
Product Categories:	Active Pharmaceutical Ingredients;Antineoplastic;Intermediates & Fine Chemicals;Pharmaceuticals;Antitumour;Bases & Related Reagents;Heterocycles;Nucleotides;Displays antitumor activity.;API;TEMODAR;Inhibitors
Mol File:	85622-93-1.mol

Temozolomide Chemical Properties

Melting point	212°C dec.
storage temp.	2-8°C
solubility	DMSO: soluble10mg/mL, clear
color	white to light brown
Merck	14,9139
InChIKey	BPEGJWRSRHCHSN-UHFFFAOYSA-N
CAS DataBase Reference	85622-93-1(CAS DataBase Reference)

Safety Information

Hazard Codes	T,Xi
Risk Statements	45-46-60-61-22-36/37/38
Safety Statements	24/25-45-36/37-26-53-36
RTECS	NJ5927050

Temozolomide Usage And Synthesis

Anticancer drugs	Temozolomide is the first effective orally-taken imidazole and tetrazine-class anticancer drug which belongs to the second generation of an alkylating agent with antitumor activity without liver metabolic activation after oral administration. It is characterized by easily penetration through the blood-brain barrier, good tolerance and being not superimposed with other drugs toxicity, and having synergistic effect with radiotherapy which is suitable for treating malignant glioma recurrence after conventional treatment such as glioblastoma multiforme tumors or degenerative astrocytoma. It is first-line drug for treatment of metastatic melanoma. Temozolomide had been first synthesized by Cancer Research UK Group, and then be transferred to the Schering-Plough Company (United States) for development. The drug is different from the existing Antineoplastic drug. It has a novel chemical structure and belongs to a four-imidazole derivative. Temozolomide does not play a direct role. At physiological pH, it is first quickly converted into active compound MTIC [5-(3-methyl-triazene-1-) imidazole-4-carboxamide] via non-enzymatically way. People think that the cytotoxicity of MTIC is mainly due to its DNA alkylation (methylation) effect. Alkylation mainly occurs in the O6 and N7 position of guanine. Basic and clinical studies of temozolomide have confirmed that it is effective in treating some of the most common glioma cells. In 1999, it has been approved for enter into market in EU and the US wherein the permitted indication in United States is mainly for second-line treatment of glioblastoma multiforme and degenerative star gliomas and approved indications of EU is for treating developing or relapsing glioblastoma multiforme which has already been subject to conventional therapy. The efficacy of temozolomide on treating glioblastoma multiforme has received more recognition in Europe.
Pharmacokinetics	This medicine can be completely oral absorbed and has a nearly 100% availability. It can exhibit a broad spectrum of activity in murine tumor model systems and can penetrate through the human blood-brain barrier. The toxic effects of temozolomide cells originate from its role in strong methylation of DNA bases. Under alkaline conditions, temozolomide can quickly be broken for formation of active methyl diazonium ion. Since the brain has a higher basicity than the surrounding tissue, so that the activation of this drug can relatively concentrate and occur at the tumor site. It has a strong anti-tumor effect with certain selectivity with its side-effect profile being alleviated, small bone marrow toxicity and improved patient tolerance.
Toxicological effects	Genetic Toxicity: Temozolomide has in vitro mutagenesis effect on bacteria (Ames test), and can cause the collapse of mammalian cell chromosomes (human peripheral blood lymphocytes clear test). Reproductive toxicity: There currently have been no reproductive toxicity performed for temozolomide, but the toxicity study of repeated medication test of rat and dog have shown that when the administered doses of 50mg/m2 and 125mg/m2, for rat and dog, respectively (calculated by body surface area, equivalent to approximately 1/4 and 5/8 of maximum recommended dosage, respectively), this product is toxic to animal testicles exhibited as syncytial cells (i.e. immature sperm) occurs and testicular atrophy. Carcinogenicity: There have been no conventional carcinogenicity studies about temozolomide yet. Giving 125 mg/m2 of temozolomide to rats in a cycle of 5 consecutive days per 28 days to (according to calculation of body surface area, it is comparable to the maximum recommended daily amount for human) for three cycles can produce breast cancer for both male and female rats. According to calculation of 25, 50, 125mg/m2 (according to the calculation of body surface area, it is roughly equivalent to 1/8 to 1/2 of the maximum recommended dosage) after administration of 6 cycles, the animals in all the dose group got breast cancer: at high-dose group, fibrosarcoma occurs in the heart, eyes, seminal vesicles, salivary glands, abdomen, uterus and prostate tissue. It is also appeared in seminal vesicle cancer, heart, nerve sheath tumors, optic nerve cancer, and Bernhard's adenocarcinoma. Moreover, adenoid tumor also occurs in other visible tissues such as animal skin, lung, pituitary, and thyroid.
The treatment of recurrent glioblastoma multiforme tumor	The treatment of Temozolomide for recurrent glioblastoma multiforme trials have confirmed upon clinical assays to be safe and effective. A randomized controlled trial in phase II have showed that 225 cases of glioblastoma multiforme patients suffering the first reoccurrence of pleomorphic glioblastoma who have been treated by temozolomide or procarbazine (every 56 days once every 28 d, oral administration of 125~150 mg/m2 per day) for 6 months, respectively, the temozolomide group of patients have got no disease deterioration with survival and overall survival rate being 21% and 60%, respectively. This was significantly higher than that in procarbazine group (8% and 44%). The average survival time and overall survival time for patients in the temozolomide group with no disease progression was 2.9 and 7.3 months, respectively, which were significantly higher than that in procarbazine group that was 1.9 and 5.8 months, respectively. The Experimental have also evaluated the health-related quality of life in both the first 3 months and 6 months after the starting of the treatment, the results also have confirmed that temozolomide group had more patients with quality of life being improved or remaining stable. The main side effect for temozolomide is transient and non-retention bone marrow suppression which is both predictable and easy to handle with a trials incidence of 24%. Temozolomide is also prone to cause moderate nausea and vomiting in patients, however these adverse reactions can be prevented with conventional antiemetic therapy. The efficacy of temozolomide for treating recurrent glioblastoma multiforme efficacy and its property of adverse reaction were significantly better than the existing standard drug procarbazine.
Clinical evaluation	Temozolomide is effective in treating newly diagnosed glioblastoma multiforme cell tumor. A small II trial results has shown that 33 cases of such patients who had been subject to temozolomide (200mg/m2) treatment where 17 patients had achieved complete or partial remission, and other four patients were in stable condition. The average time from the disease remission to disease progression for 17 patients was seven months, and was two months for the treatment of non-responders with their average survival time being 12 months and 6 months. But the effect of temozolomide in treating newly diagnosed degenerative astrocytomas remains unclear. Temozolomide is of high efficacy on glioma cells, especially has a significant effect on the most common pleomorphic glioblastoma. No matter in tumor response rates, or in patient survival and tolerability it all has a good effect. More importantly, the quality of patients’ life is significantly better than the existing standard drug procarbazine, moving a big step toward the treatment of tumors using this kind of drug. The first-line position of Temozolomide in treatment of progressive metastatic melanoma has been affirmed in clinical assays. Applications for applying it widely in Europe and the United States are being conducted. A recent randomized controlled trial results in III phase have shown about the 305 cases of these patients who subjected to temozolomide (200 mg/m2) and dacarbazine (every 21 days once a 5d, 250 mg/m2 per day) treatment, temozolomide group of patients had a overall survival and treatment response rates of 7.9 months and 13.5%, respectively, which was better than that of 5.7 months and 12.1% as observed in dacarbazine group. Patients in Temozolomide group had a better tolerance than dacarbazine group with its life-qualify evaluation (reflected by reduced physiological function) also significantly better than dacarbazine group (the rate of decline was 18% and 42% after three months of treatment, respectively). Melanoma skin tumors are rare skin cancer, even though it accounts for only about 4% of all skin cancers, but the mortality rate accounted for about 79% of all skin cancer. The current standard drug for treating it is still dacarbazine. Temozolomide has exhibited high clinical efficacy towards glial cells and melanoma, and thus is worthy of attention. The above information is edited by the Chemicalbook of Dai Xiongfeng.
Patent No	DE 3237255; US 5260921
Chemical Properties	It is crystallized from dichloromethane, m.p. 212 °C (decomposition). UV maximal absorption wavelength (95% ethanol): 327nm.
Uses	Antineoplastic agents. Spontaneous and rapid degradation and produce the active metabolite MTIC in vivo, yielding anti-tumor effect.
Production methods	Amino-4-carboxamido-imidazole is first subject to nitrite diazotization, and has reaction with methyl isocyanate in dichloromethane for cyclization to obtain ammonium temozolomide.
Chemical Properties	Off-White to Light-Pink Crystalline Solid
Uses	Imidazotetrazine alkylating agent. An antineoplastic.
Uses	inhibits cancer cells similar to paclitaxel effective against paclitaxel-resistant tumours
Uses	An apoptosis inducer which causes arrest at the G2/M cell cycle checkpoint.
Definition	ChEBI: An imidazotetrazine that is 3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine which is substituted at positions 3, 4, and 8 by methyl, oxo, and carboxamide groups, respectively. A prodrug for MTIC (5-(3-methyltriaz-1-en-1-yl)-1H-i idazole-4-carboxamide, formed by spontaneous hydrolysis of temozolomide in the body), it is used as an oral alkylating agent for the treatment of newly diagnosed malignant glioblastoma multiforme (concomitantly with radiotherapy) and malignant melanoma.
Biological Activity	DNA methylating, chemotherapeutic agent. Displays antitumor activity against a board spectrum of tumors, including leukemias, lymphomas and solid tumors (IC 50 = 5.0 μ M for cytotoxicity against mouse TLX5 lymphoma cells).